Coverage
-
March 13, 2026
Sandoz Inc. is appealing after a Virginia federal court ruled it should have brought claims accusing Amgen of blocking competition for the Enbrel biosimilar in a previous patent dispute, according to a Friday notice.
2 other articles on this case.
View all »